Design of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian... | Download Scientific Diagram
Saturday, May 30, :00 PM - 9:00 PM The Peabody Orlando Orlando, Florida Ovarian Cancer: Recent Developments in the Standard of Care and Emerging. - ppt download
A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer | NEJM
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
PDF) Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial
Cytoreductive surgery before chemotherapy benefits women with recurrent ovarian cancer
Advances in ovarian cancer, from biology to treatment | Nature Cancer
Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer☆ - ESMO Open
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer
Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base - Gynecologic Oncology
gyncsm Community: July 8, 2020 - Gyn Cancer Research News and Reading Scientific Posters Chat
Frontiers | Prediction Models for Complete Resection in Secondary Cytoreductive Surgery of Patients With Recurrent Ovarian Cancer
AGO-OVAR DESKTOP III (Protocol AGO - OVAR OP.4) - ppt video online download
New Data Support Debulking to Prolong Survival in Women With Platinum-Sensitive Recurrent Ovarian Cancer
Prognostic value of radiological recurrence patterns in ovarian cancer - Gynecologic Oncology
Shannon Westin on Twitter: "Why the difference between GOG213 & DESKTOP III/SOC-1?? How do we use this information to make decisions as patients and physicians? #ASCO20 #SGOatASCO #gyncsm" / Twitter
Fumiko Ladd Chino, MD Twitter'da: "🚨@Oncoalert: Dr Helen MacKay summarizes #gyncsm highlights including Desktop III (compared to Soc-1 and GOG-213) for recurrent epithelial #ovariancancer showing a 7.7 month OS benefit from 2ndary
PPT - An Oncology Exchange Activity PowerPoint Presentation, free download - ID:5600388
Clinical Conundrums: Choosing the Best Management Approaches in Patients With Ovarian Cancer Thomas J. Herzog, MD Director, Division of Gynecologic Oncology. - ppt download
AGO Score As a Predictor of Surgical Outcome at Secondary Cytoreduction in Patients with Ovarian Cancer | Anticancer Research
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer | NEJM
Diapositiva 1
A trial looking at surgery for ovarian cancer that has come back (DESKTOP 3, ENGOT ov20) | Cancer Research UK
Epithelial ovarian cancer - The Lancet
